Fulcrum therapeutics announces proposed public offering of common stock

Cambridge, mass., jan. 19, 2021 (globe newswire) -- fulcrum therapeutics, inc. (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock. all of the shares are being offered by fulcrum. in addition, fulcrum expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering.
FULC Ratings Summary
FULC Quant Ranking